Oncology Institute (NASDAQ:STLN) Stock Sale Revealed by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 22nd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Price Performance

Shares of NASDAQ STLN opened at $6.59 on Wednesday. The firm has a 50-day moving average of $6.47. Oncology Institute, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $7.13.

Oncology Institute (NASDAQ:STLN) last released its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $161.28 million during the quarter, compared to analyst estimates of $152.80 million. As a group, sell-side analysts forecast that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncology Institute

Several institutional investors and hedge funds have recently made changes to their positions in STLN. State Street Corp bought a new stake in Oncology Institute in the 2nd quarter valued at $8,432,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oncology Institute in the second quarter valued at approximately $111,000. WINTON GROUP Ltd bought a new stake in shares of Oncology Institute in the second quarter valued at approximately $102,000. Engineers Gate Manager LP bought a new stake in shares of Oncology Institute in the second quarter valued at approximately $67,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Oncology Institute in the second quarter valued at approximately $396,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Jorey Chernett purchased 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the transaction, the insider owned 10,660,858 shares of the company’s stock, valued at approximately $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the transaction, the director owned 411,976 shares in the company, valued at $2,681,963.76. The trade was a 42.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

STLN has been the subject of several recent research reports. Needham & Company LLC increased their price target on Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Lake Street Capital assumed coverage on Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings began coverage on Oncology Institute in a research report on Thursday, August 6th. They set a “sell (d-)” rating on the stock. Finally, BTIG Research upped their price objective on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.